NIH Offers Ebola Vaccine Invention to Private Firms
Published Date: 7/24/2026
Notice
Summary
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Analyzed Economic Effects
5 provisions identified: 4 benefits, 1 costs, 0 mixed.
NIH Offers Ebola Vaccine For Licensing
The NIH is offering a new rVSV-BDBV Ebola vaccine invention (HHS Ref. No. E-122-2026-0) for companies to license to commercialize. Businesses can contact Terrence Joyce (301-761-7235) or the NIAID Technology Transfer Office to request licensing information and start development.
Collaborative Research Opportunities Available
NIAID is seeking statements of capability or interest for collaborative research to further develop, evaluate, or commercialize the rVSV-BDBV vaccine. Interested parties should contact Terrence Joyce at 301-761-7235 or the NIAID Technology Transfer Office and may enter collaboration agreements.
Pre-Clinical Vaccine Shows Rapid Protection
The vaccine is at the pre-clinical stage and a single intramuscular dose protected nonhuman primates from disease within 3 days of vaccination. The licensable materials include the recombinant rVSV-BDBV vaccine and the DNA plasmid pATX-VSV[Delta]G-BDBV GP to support development and manufacturing.
Foreign Patent Coverage May Be Available
The notice states that foreign patent applications are filed on selected inventions to extend market coverage and those foreign filings may also be available for licensing. This can affect market rights and geographic scope for licensees.
Confidential Disclosure Agreement Required
A signed Confidential Disclosure Agreement (CDA) is required to receive copies of unpublished information related to the invention from NIAID. Companies must sign a CDA before obtaining technical details for licensing or collaboration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
2026-14981, Government Owned Invention Available for License: Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia (AML)
The government has developed special T cell receptors that can target a tough type of blood cancer called acute myeloid leukemia (AML), especially in patients with a specific genetic marker. These new receptors promise safer, more precise treatment with fewer side effects than current options. Researchers and companies can now license this invention to help bring this exciting therapy to patients faster.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
2026-14848, Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS
The National Institutes of Health plans to give Modala Bio an exclusive license to use new RXFP1 agonist inventions that could help treat diseases like cancer, heart failure, and fibrosis. This means Modala Bio gets special rights to develop and sell these promising medicines worldwide. If you want to comment or apply for a license, you have until August 24, 2026, so don’t miss out!
2026-14752, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in August 2026 to review and evaluate important grant and contract proposals. These meetings protect private info and trade secrets while deciding who gets funding to fight antibiotic resistance, support schizophrenia research, and boost medical tech. If you’re involved in these fields, keep an eye on these dates—they could impact future research dollars and projects.
2026-14666, National Institute of Neurological Disorders and Stroke; Notice of Meeting
The National Institute of Neurological Disorders and Stroke is hosting a free, virtual meeting on August 24, 2026, to talk about Parkinson’s disease research, care, and services. This meeting affects people with Parkinson’s, their families, and organizations working on the disease, as it will share updates and plan a federal list of Parkinson’s programs. Public comments are welcome until August 10, giving everyone a chance to join the conversation and help shape future efforts.
Previous / Next Documents
Previous: 2026-14965, Agency Information Collection Activities; Extension, Without Change, of a Currently Approved Collection: Request for Fee Waiver
The Department of Homeland Security is keeping its current form for asking to waive immigration fees, with no changes. They’re asking the public to share thoughts by August 24, 2026, but this won’t cost anyone extra or change how the form works. This is just a routine step to keep the fee waiver request available and easy to use.
Next: 2026-14967, Foreign-Trade Zone (FTZ) 45; Authorization of Limited Production Activity; SSI Shredding Systems, Inc.; (Industrial Shredders and Compactors); Wilsonville and Portland, Oregon
SSI Shredding Systems in Oregon got the green light to start limited production of industrial shredders and compactors in their Foreign-Trade Zone facilities. They must pay duties on steel and aluminum parts unless special trade rules apply. This change kicks in now and helps SSI grow while following trade rules.